Servier ordered on appeal to reimburse more than 415 million to social security organizations

This is the conclusion of an appeal trial which lasted six months. The Servier group, which marketed the Mediator, was sentenced on appeal, Wednesday December 20, to a fine of more than 7 million euros and to reimburse more than 415 million euros to social security organizations and mutual societies.

The pharmaceutical group was found guilty of all the offenses with which it was charged, including the offense of fraud for which it was acquitted at first instance.

Servier held responsible for hundreds of deaths

Marketed in 1976 as an adjuvant to antidiabetic treatments, but often unduly prescribed as an appetite suppressant until its ban in 2009, Mediator, a flagship molecule of Servier, has caused serious cardiovascular lesions in thousands of patients. He is held responsible for hundreds of deaths.

In March 2021, during the trial at first instance, the Paris criminal court sentenced the six companies of the Servier laboratory to a fine of 2.7 million euros, estimating that it had “from 1995, enough information to become aware of the mortal risks” related to the Mediator.

Read also: Article reserved for our subscribers Irène Frachon: “This Mediator trial is a missed opportunity”

The prosecution accuses Servier in particular of having continued to market Mediator without informing patients of the risks involved, with the aggravating circumstance that this risk affected their state of health.

In total, 7,650 people became civil parties to the trial, most of them in the section “deception”. Some 5,000 other cases for homicides or involuntary injuries are still being investigated by the Paris prosecutor’s office, paving the way for a probable second Mediator trial in the coming years.

Read also: Article reserved for our subscribers At the Mediator trial, the embarrassing internal note from Servier laboratories in 1999

The World with AFP

source site-27